BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 16508892)

  • 1. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.
    Yeh YW
    Clin Neuropharmacol; 2011; 34(4):135-6. PubMed ID: 21768798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole as a dopamine partial agonist: positive and negative effects.
    Glick ID; Duggal V; Hodulik C
    J Clin Psychopharmacol; 2006 Feb; 26(1):101-3. PubMed ID: 16415723
    [No Abstract]   [Full Text] [Related]  

  • 4. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aripiprazole in the treatment of schizophrenia].
    Bridler R
    Praxis (Bern 1994); 2005 Jun; 94(23):975-7. PubMed ID: 16001540
    [No Abstract]   [Full Text] [Related]  

  • 8. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do dopamine partial agonists have partial efficacy as antipsychotics?
    Stahl SM
    CNS Spectr; 2008 Apr; 13(4):279-82. PubMed ID: 18408646
    [No Abstract]   [Full Text] [Related]  

  • 10. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
    Kessler RM
    Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411
    [No Abstract]   [Full Text] [Related]  

  • 12. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
    Crismon ML; DeLeon A; Miller AL
    Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
    [No Abstract]   [Full Text] [Related]  

  • 13. [A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
    Kerpel-Fronius S; Lóránt M
    Neuropsychopharmacol Hung; 2004 Dec; 6(4):177-84. PubMed ID: 15825673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole in the treatment of Alzheimer's disease.
    De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
    Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the safety and tolerability of aripiprazole.
    Pae CU
    Expert Opin Drug Saf; 2009 May; 8(3):373-86. PubMed ID: 19505266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.
    Shim JC; You YS; Kelly DL
    J Clin Psychopharmacol; 2008 Jun; 28(3):353-4. PubMed ID: 18480699
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial dopamine agonists in schizophrenia.
    Launer M
    Hosp Med; 2005 May; 66(5):300-3. PubMed ID: 15920862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.